Aimmune therapeutics, inc. (AIMT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15Sep'14Jun'14
Product revenue, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and operating expenses
Cost of revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses
Research and development

129,134

123,987

126,891

128,024

131,290

133,420

129,045

118,417

105,354

89,325

77,629

72,454

62,083

54,642

41,534

28,777

0

0

0

0

0

Selling, general and administrative

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and operating expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

125,817

114,360

101,601

-

81,921

69,503

59,444

51,698

43,949

39,306

34,433

30,086

26,885

23,716

21,609

0

0

0

0

0

Total operating expenses

-

249,804

241,251

229,625

-

215,341

198,548

177,861

157,052

133,274

116,935

106,887

92,169

81,527

65,250

50,386

0

0

0

0

0

Loss from operations

-280,059

-249,804

-241,251

-229,625

-220,250

-215,341

-198,548

-177,861

-157,052

-133,274

-116,935

-106,887

-92,169

-81,527

-65,250

-50,386

0

0

0

0

0

Interest income

4,928

5,851

6,408

6,487

6,177

4,984

0

0

0

-

-

-

-

-

-

-

-

-

-

-

0

Interest expense

6,001

4,916

3,694

2,462

1,228

113

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

1,275

1,088

-105

-156

-144

-221

346

906

1,491

2,005

1,700

1,358

998

703

511

357

0

0

0

-

-

Loss before provision for income taxes

-279,857

-247,781

-238,642

-225,756

-215,445

-210,691

-194,785

-174,904

-154,882

-131,269

0

0

0

-

-

-

-

-

-

-

-

Provision for income taxes

806

716

-45

88

73

61

135

0

0

0

-

-

-

-

-

-

-

-

-

-

-

Net loss

-280,631

-248,497

-238,597

-225,844

-215,518

-210,752

-194,920

-175,010

-154,955

-131,325

-115,235

-105,529

-91,171

-80,824

-64,739

-50,029

0

0

0

0

0

Other comprehensive loss, net of tax:
Foreign currency translation adjustment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale investments

90

188

0

0

0

-

-

-

-

-81

-88

-166

-128

61

100

0

0

0

-

-

-

Comprehensive loss

-280,563

-248,309

0

0

0

-

-

-

-

-131,406

-115,323

-105,695

-91,299

-80,763

-64,639

-49,912

0

0

0

0

-

Net loss per share, basic and diluted

-1.34

-1.06

-1.03

-1.01

-0.87

-0.95

-0.89

-0.91

-0.92

-0.81

-0.63

-0.65

-0.52

-0.56

-0.53

-0.43

-0.37

-0.36

-1.60

-1.07

-0.94

Weighted average shares used in computing net loss per common share, basic and diluted

64,514

63,257

62,619

62,334

62,022

-

-

-

-

50,847

50,458

50,230

50,069

45,513

41,997

41,800

41,694

25,149

4,619

2,926

2,926